Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

22,773 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study.
Lu S, Fang J, Li X, Cao L, Zhou J, Guo Q, Liang Z, Cheng Y, Jiang L, Yang N, Han Z, Shi J, Chen Y, Xu H, Zhang H, Chen G, Ma R, Sun S, Fan Y, Li J, Luo X, Wang L, Ren Y, Su W. Lu S, et al. Among authors: jiang l. Lancet Respir Med. 2021 Oct;9(10):1154-1164. doi: 10.1016/S2213-2600(21)00084-9. Epub 2021 Jun 21. Lancet Respir Med. 2021. PMID: 34166627 Clinical Trial.
A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of paclitaxel-carboplatin alone or with endostar for advanced non-small cell lung cancer.
Han B, Xiu Q, Wang H, Shen J, Gu A, Luo Y, Bai C, Guo S, Liu W, Zhuang Z, Zhang Y, Zhao Y, Jiang L, Zhou J, Jin X. Han B, et al. Among authors: jiang l. J Thorac Oncol. 2011 Jun;6(6):1104-9. doi: 10.1097/JTO.0b013e3182166b6b. J Thorac Oncol. 2011. PMID: 21532504 Free article. Clinical Trial.
[A multicenter, randomized, double-blind, placebo-controlled safety study to evaluate the clinical effects and quality of life of paclitaxel-carboplatin (PC) alone or combined with endostar for advanced non-small cell lung cancer (NSCLC)].
Han BH, Xiu QY, Wang HM, Shen J, Gu AQ, Luo Y, Bai CX, Guo SL, Liu WC, Zhuang ZX, Zhang Y, Zhao YZ, Jiang LY, Shi CL, Jin B, Zhou JY, Jin XQ. Han BH, et al. Zhonghua Zhong Liu Za Zhi. 2011 Nov;33(11):854-9. Zhonghua Zhong Liu Za Zhi. 2011. PMID: 22335953 Clinical Trial. Chinese.
Low frequency KRAS mutations in colorectal cancer patients and the presence of multiple mutations in oncogenic drivers in non-small cell lung cancer patients.
Jiang L, Huang J, Morehouse C, Zhu W, Korolevich S, Sui D, Ge X, Lehmann K, Liu Z, Kiefer C, Czapiga M, Su X, Brohawn P, Gu Y, Higgs BW, Yao Y. Jiang L, et al. Cancer Genet. 2013 Sep-Oct;206(9-10):330-9. doi: 10.1016/j.cancergen.2013.09.004. Epub 2013 Oct 2. Cancer Genet. 2013. PMID: 24200637 Free article.
Is there a progression-free survival benefit of first-line crizotinib versus standard chemotherapy and second-line crizotinib in ALK-positive advanced lung adenocarcinoma? A retrospective study of Chinese patients.
Cui S, Zhao Y, Dong L, Gu A, Xiong L, Qian J, Zhang W, Niu Y, Pan F, Jiang L. Cui S, et al. Among authors: jiang l. Cancer Med. 2016 Jun;5(6):1013-21. doi: 10.1002/cam4.659. Epub 2016 Feb 16. Cancer Med. 2016. PMID: 26880708 Free PMC article.
22,773 results
You have reached the last available page of results. Please see the User Guide for more information.